Reviewer’s report

Title: The role of the adipocytokines vaspin and visfatin in vascular endothelial function and insulin resistance in obese children

Version: 0 Date: 15 Jul 2019

Reviewer: Decio Armanini

Reviewer's report:

The authors have evaluated the role of vaspin and visfatin in vascular endothelial function and insulin resistance in obese children

I suggest controlling all the text for typing errors
For example, abstract; earlyonset line 36 and vaspins line 59

General comments:

the authors should explain the clinical implications of vaspin in humans
background line 7: obesity leads to insulin resistance and type 2 diabetes. Maybe is insulin resistance that leads to obesity and diabetes.
Second page of background; lines 1-4: vaspin improves glucose tolerance insulin sensitivity and altered gene expression, From this study it seems that vaspin has a positive effect on insulin resistance
The Authors also report that: vaspin has a role in pathogenesis of insulin resistance and has a negative effect stimulating the secretion of interleukin 6 and TN alpha in monocytes.

Is visfatin produced by adipocytes r by inflammatory cells considering that obesity is always linked to inflammation?

Anthropometric measurements line 51 glucose and insulin were measured at 120 min after glucose administration. These data are very important and should be reported in the results

Line 12 correct minsusing

Results why the authors say "as expected"?

Some of the female subjects should have had the menarche and I suggest evaluating separately male and female

Discussion lines 29 Adipocytes may play an important role in endothelial dysfunction and vascular inflammation but does not affect insulin resistance. Is this sentence related only to visfatin and vasfin or to all adipokines?
In the third page of the discussion the authors report that vispatin can bind to insulin receptors at a site separate from insulin. Please explain these discrepancies. It should be important to evaluate the value of insulin and vispatin al 120 minutes from glucose administration.

From this study it is not clear whether vispatin has a positive role improving insulin resistance or a negative one both on insulin resistance and endothelial function.

Table 1 please explain the reason to selecting two groups with a highly different BMI (17+/-2 and 28+/-3).

In conclusion the study is of interest but the discussion should clarify the positive or negative role of these adipokines in insulin resistance and inflammatory reaction.

Please include all comments for the authors in this box rather than uploading your report as an attachment. Please only upload as attachments annotated versions of manuscripts, graphs, supporting materials or other aspects of your report which cannot be included in a text format.

Please overwrite this text when adding your comments to the authors.

**Are the methods appropriate and well described?**
If not, please specify what is required in your comments to the authors.

Yes

**Does the work include the necessary controls?**
If not, please specify which controls are required in your comments to the authors.

Yes

**Are the conclusions drawn adequately supported by the data shown?**
If not, please explain in your comments to the authors.

No

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

No competing interests
I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.